Invesaro

Stocks Comparison

Smith & Nephew vs STERIS: revenue, profit, margins and growth compared

Smith & Nephew brought in $6.2B of revenue in fiscal 2025, STERIS $5.9B in fiscal 2026. Revenue changed by +6.1% at Smith & Nephew and +8.7% at STERIS on the year before, so STERIS grew faster. Smith & Nephew kept 10.1% of its revenue as net profit, STERIS 13.2%.

Side by side, latest fiscal year

SNNSTE
Fiscal year endedFY2025 (December 31, 2025)FY2026 (March 31, 2026)
Revenue$6.2B$5.9B
Revenue growth+6.1%+8.7%
Net income$625M$782.3M
Net margin10.1%13.2%
Free cash flown/a$972.4M
Free cash flow marginn/a16.4%
Earnings per share (diluted)$0.72$7.93
Cash$557M$439.6M
Debt$3.1B$1.8B
Price to earningsn/a26.6
Market value$11.5B$20.6B
Dividend yieldn/a1.17%
Rank by revenue in sector#56 of 742 · Health care#58 of 742 · Health care

Over the years

Revenue
SNN FY2018: $4.9BSNN FY2019: $5.1BSNN FY2020: $4.6BSNN FY2021: $5.2BSNN FY2022: $5.2BSNN FY2023: $5.5BSNN FY2024: $5.8BSNN FY2025: $6.2BSTE FY2019: $2.8BSTE FY2020: $3BSTE FY2021: $3.1BSTE FY2022: $4.2BSTE FY2023: $4.5BSTE FY2024: $5.1BSTE FY2025: $5.5BSTE FY2026: $5.9BFY18FY19FY20FY21FY22FY23FY24FY25FY26
SNN $6.2BSTE $5.9B
Net income
SNN FY2018: $663MSNN FY2019: $600MSNN FY2020: $448MSNN FY2021: $524MSNN FY2022: $223MSNN FY2023: $263MSNN FY2024: $412MSNN FY2025: $625MSTE FY2019: $303.7MSTE FY2020: $407.7MSTE FY2021: $397.4MSTE FY2022: $243.9MSTE FY2023: $107MSTE FY2024: $378.2MSTE FY2025: $614.6MSTE FY2026: $782.3MFY18FY19FY20FY21FY22FY23FY24FY25FY26
SNN $625MSTE $782.3M
Net margin
SNN FY2018: 13.5%SNN FY2019: 11.7%SNN FY2020: 9.8%SNN FY2021: 10.1%SNN FY2022: 4.3%SNN FY2023: 4.7%SNN FY2024: 7.1%SNN FY2025: 10.1%STE FY2019: 10.9%STE FY2020: 13.5%STE FY2021: 12.8%STE FY2022: 5.8%STE FY2023: 2.4%STE FY2024: 7.4%STE FY2025: 11.3%STE FY2026: 13.2%FY18FY19FY20FY21FY22FY23FY24FY25FY26
SNN 10.1%STE 13.2%
Revenue growth
SNN FY2019: +4.8%SNN FY2020: -11.2%SNN FY2021: +14.3%SNN FY2022: +0.1%SNN FY2023: +6.4%SNN FY2024: +4.7%SNN FY2025: +6.1%STE FY2020: +8.9%STE FY2021: +2.5%STE FY2022: +35.9%STE FY2023: +7.4%STE FY2024: +13.3%STE FY2025: +6.2%STE FY2026: +8.7%FY19FY20FY21FY22FY23FY24FY25FY26
SNN +6.1%STE +8.7%
Free cash flow
STE FY2019: $349.8MSTE FY2020: $376MSTE FY2021: $450.4MSTE FY2022: $397.2MSTE FY2023: $395MSTE FY2024: $613MSTE FY2025: $778MSTE FY2026: $972.4MFY19FY20FY21FY22FY23FY24FY25FY26
SNNSTE $972.4M

Fiscal years as each company reports them; the two may end in different months.

Questions about Smith & Nephew and STERIS

Which is bigger by revenue, Smith & Nephew or STERIS?

Smith & Nephew is bigger by revenue: $6.2B in fiscal 2025, against $5.9B for STERIS in fiscal 2026.

Which keeps more of its revenue as profit, Smith & Nephew or STERIS?

Smith & Nephew had a net margin of 10.1% in fiscal 2025; STERIS had 13.2% in fiscal 2026.

Which grew revenue faster, Smith & Nephew or STERIS?

In their latest fiscal years revenue changed by +6.1% at Smith & Nephew and +8.7% at STERIS.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies